Table 1.
Cross tabulation of the index test results by patient brucellosis case status (n = 218, of which 14 were brucellosis cases and 204 were non-brucellosis cases).
| Index test | Index test result | Brucellosis case status | |||
|---|---|---|---|---|---|
| Non-brucellosis case | Brucellosis case | Total | Percentage positive by test (95% CI) | ||
| RBT 1:2 | Negative | 197 | 2 | 199 | 8.7 (5.3–13.3) |
| Positive | 7 | 12 | 19 | ||
| RBT 1:8 | Negative | 202 | 3 | 205 | 6.0 (3.2–10.0) |
| Positive | 2 | 11 | 13 | ||
| Amitech | Negative | 142 | 9 | 151 | 30.7 (24.7–37.3) |
| Positive | 62 | 5 | 67 | ||
| Arkray | Negative | 133 | 5 | 138 | 36.7 (30.3–43.5) |
| Positive | 71 | 9 | 80 | ||
| Eurocell | Negative | 113 | 7 | 120 | 45.0 (38.2–51.8) |
| Positive | 91 | 7 | 98 | ||
| Fortress | Negative | 153 | 10 | 163 | 25.2 (19.6–31.5) |
| Positive | 51 | 4 | 55 | ||
| cELISA | Negative | 182 | 1 | 183 | 16.1 (11.4–21.6) |
| Positive | 22 | 13 | 35 | ||
RBT the Rose Bengal test, cELISA competitive enzyme-linked immunosorbent assay, CI confidence interval.